AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal
AIM ImmunoTech (NYSE American: AIM), an immuno-pharma company focused on cancer, immune disorders, and viral diseases therapeutics, announced receiving a delisting notification from NYSE American on April 4, 2025. The Exchange suspended trading of AIM's common stock due to its low selling price, citing Section 1003(f)(v) of the NYSE American Company Guide.
The company plans to appeal the determination to the Exchange's Listing Qualifications Panel, though success is not guaranteed. Trading of AIM's common stock is expected to transition to the Pink Open Market starting April 7, 2025.
AIM ImmunoTech (NYSE American: AIM), un'azienda biofarmaceutica focalizzata su terapie per il cancro, disturbi immunitari e malattie virali, ha annunciato di aver ricevuto una notifica di esclusione dalla NYSE American il 4 aprile 2025. L'Exchange ha sospeso le contrattazioni delle azioni ordinarie di AIM a causa del loro basso prezzo di vendita, citando la Sezione 1003(f)(v) della Guida alle Aziende NYSE American.
L'azienda prevede di fare appello alla decisione del Comitato per le Qualifiche di Quotazione dell'Exchange, anche se il successo non è garantito. Le contrattazioni delle azioni ordinarie di AIM dovrebbero passare al Mercato Aperto Pink a partire dal 7 aprile 2025.
AIM ImmunoTech (NYSE American: AIM), una empresa biofarmacéutica centrada en terapias para el cáncer, trastornos inmunitarios y enfermedades virales, anunció que recibió una notificación de exclusión de NYSE American el 4 de abril de 2025. La Bolsa suspendió la negociación de las acciones ordinarias de AIM debido a su bajo precio de venta, citando la Sección 1003(f)(v) de la Guía de Empresas de NYSE American.
La empresa planea apelar la decisión al Panel de Calificaciones de Cotización de la Bolsa, aunque el éxito no está garantizado. Se espera que la negociación de las acciones ordinarias de AIM pase al Mercado Abierto Pink a partir del 7 de abril de 2025.
AIM ImmunoTech (NYSE American: AIM), 암, 면역 장애 및 바이러스 질병 치료에 집중하는 면역 제약 회사는 2025년 4월 4일 NYSE American로부터 상장 폐지 통지를 받았다고 발표했습니다. 거래소는 AIM의 보통주 거래를 낮은 판매 가격으로 인해 중단했으며, NYSE American 회사 가이드의 섹션 1003(f)(v)를 인용했습니다.
회사는 결정에 대해 항소할 계획이지만 성공이 보장되지는 않습니다. AIM의 보통주 거래는 2025년 4월 7일부터 핑크 오픈 마켓으로 전환될 것으로 예상됩니다.
AIM ImmunoTech (NYSE American: AIM), une entreprise biopharmaceutique axée sur les thérapies contre le cancer, les troubles immunitaires et les maladies virales, a annoncé avoir reçu une notification de radiation de la NYSE American le 4 avril 2025. La Bourse a suspendu la négociation des actions ordinaires d'AIM en raison de leur faible prix de vente, en citant la section 1003(f)(v) du Guide des entreprises de la NYSE American.
L'entreprise prévoit de contester la décision auprès du Comité des qualifications de cotation de la Bourse, bien que le succès ne soit pas garanti. La négociation des actions ordinaires d'AIM devrait passer au Pink Open Market à partir du 7 avril 2025.
AIM ImmunoTech (NYSE American: AIM), ein biopharmazeutisches Unternehmen, das sich auf Therapien für Krebs, Immunerkrankungen und Viruserkrankungen konzentriert, gab bekannt, dass es am 4. April 2025 eine Delisting-Benachrichtigung von NYSE American erhalten hat. Die Börse hat den Handel mit den Stammaktien von AIM aufgrund ihres niedrigen Verkaufspreises ausgesetzt und dabei auf Abschnitt 1003(f)(v) des NYSE American Company Guide verwiesen.
Das Unternehmen plant, die Entscheidung anzufechten beim Listing Qualifications Panel der Börse, obwohl der Erfolg nicht garantiert ist. Der Handel mit den Stammaktien von AIM wird voraussichtlich ab dem 7. April 2025 auf den Pink Open Market übergehen.
- Company maintaining appeal rights to potentially retain NYSE American listing
- NYSE American suspended trading and initiated delisting proceedings
- Company forced to move to Pink Open Market, a less prestigious trading venue
- Low stock price triggering delisting indicates significant market value deterioration
OCALA, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (“AIM” or the “Company”) (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19, reported that on April 4, 2025, it received notification from NYSE Regulation of the NYSE American LLC (the “NYSE American” or the “Exchange”) that it had suspended trading of the Company’s common stock and of its determination to commence delisting proceedings of the Company’s common stock from the Exchange pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the Company’s common stock. The Company plans to appeal the determination to the Exchange’s Listing Qualifications Panel, although there can be no assurance that any such appeal will be successful.
The Company’s common stock is expected to begin trading on the Pink Open Market on April 7, 2025.
Additional details are included in, and the description above is qualified in its entirety by, AIM’s Current Report on Form 8-K filed with the SEC on April 4, 2025, which will be made available under “Investors” – “SEC Filings” at aimimmuno.com.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. The use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar words or expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the Company’s intention to regain compliance with the listing requirements of the NYSE American and its ability to do so. These statements involve risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. The forward-looking statements contained herein speak only as of the date hereof, and the Company assumes no obligation to update any forward-looking statements, whether as a result of new information, subsequent events or otherwise, except as required by law.
Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com
FAQ
Why is AIM ImmunoTech (AIM) being delisted from NYSE American?
When will AIM stock begin trading on the Pink Open Market?
What actions is AIM taking regarding the NYSE American delisting notice?
When did AIM receive the NYSE American delisting notification?
